Androgen therapy in combination with granulocyte colony-stimulating factor and erythropoietin in a patient with refractory anemia.
Initial treatment with androgen (metenolone acetate) alone for 19 weeks had no effect in a 45-year-old Japanese female with refractory anemia (RA). The patient achieved trilineage hematologic recovery after addition of recombinant human granulocyte colony-stimulating factor (G-CSF) and recombinant human erythropoietin (Epo) to the androgen therapy. Anemia progressed after the cessation of metanolone acetate, but was effectively treated by the readministration of metenolone acetate. Thus, the androgen therapy in combination with hematopoietic growth factors such as G-CSF and/or Epo may be effective in patients with RA.
Katayama
Y
Y
Second Department of Internal Medicine, Okayama University Medical School, Japan.
Kojima
K
K
Omoto
E
E
Harada
M
M
D000753:Anemia, Refractory / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008710:Methenolone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D008710:Methenolone; C033244:methenolone acetate